[Hemorrhage treatment: Evaluation of the proper use of fibrinogen concentrate].

Fiche publication

Date publication

février 2017

Journal

Therapie

Auteurs

Membres identifiés du Cancéropôle Est :
Dr FAGNONI Philippe

Tous les auteurs :
Howlett J, Prudent C, De Maistre E, Fagnoni P, Lazzarotti A

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/28336161

Résumé

An increase in fibrinogen concentrate prescriptions was noticed in 2015 after several guidelines regarding their use were published. We tried to evaluate if they were used appropriately. To evaluate the conformity of the prescriptions to these guidelines, we searched for each prescription if a dosage of blood fibrinogen was made, if its result was below the limit recommended to prescribe fibrinogen concentrate, and if the posology was in line with the recommendations. Effect and security of the treatment was also evaluated. We analyzed 202 prescriptions for 117 patients. The indications are respected except for one prescription for which we could not find it. The blood fibrinogen is measured for 76% of the prescriptions, 59% of the results are below the limit recommended to prescribe. The posology is conforming to the guidelines for 73% of the prescriptions, it is below the dose recommended for 20%. Patients who were prescribed low doses seemed less at risk than the others which questions the necessity of the prescriptions. The guidelines respect depends on the emergency of the prescription situation. It would be interesting to conduct a prospective study to better explain why doses below those recommended are prescribed.